Hartoun Hartounian
Corporate Officer/Principal presso San Diego Tech Coast Angels
Profilo
Hartoun Hartounian was the founder of Protagenic Therapeutics, Inc. (founded in 1994) where he held the title of Director.
He is currently a Member at San Diego Tech Coast Angels.
Hartounian's former positions included President, Chief Executive Officer & Director at Vyteris, Inc. (2011), Director-Process Development at Monsanto Co. (1998-2001), Director at Protagenic Therapeutics, Inc. (2006-2010), and President, Chief Operating Officer & Director at MicroIslet, Inc. (2006).
He was also an Adjunct Assistant Professor at Drexel University.
Hartounian received a graduate degree from the University of California, Los Angeles and a doctorate from the University of Delaware.
Posizioni attive di Hartoun Hartounian
| Società | Posizione | Inizio |
|---|---|---|
| San Diego Tech Coast Angels | Corporate Officer/Principal | - |
Precedenti posizioni note di Hartoun Hartounian
| Società | Posizione | Fine |
|---|---|---|
Vyteris, Inc.
 Vyteris, Inc. Pharmaceuticals: MajorHealth Technology Vyteris, Inc. develops, manufactures and commercializes pharmaceutical products. It is engaged in the process of developing first active drug delivery patch to receive marketing clearance from the U.S. Food and Drug Administration. The drug delivery patch technology allows precise dosing, giving physicians and patients control in the rate, dosage and pattern of drug delivery that may result in considerable therapeutic, economical, and lifestyle advantages over existing methods of drug administration. The company was founded on July 19, 2000 and is headquartered in Fair Lawn, NJ. | Presidente | 09/08/2011 |
MicroIslet, Inc.
 MicroIslet, Inc. Miscellaneous Commercial ServicesCommercial Services MicroIslet, Inc. operates as a biotechnology company, which researches, develops, and commercializes patented technologies in the field of transplantation therapy for people with insulin-dependent diabetes. The company was founded on August 21, 1998 and is headquartered in San Diego, CA. | Presidente | 17/02/2006 |
| MONSANTO | Corporate Officer/Principal | 01/01/2001 |
| PROTAGENIC THERAPEUTICS, INC. | Fondatore | - |
Protagenic Therapeutics, Inc. /Old/
 Protagenic Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Protagenic Therapeutics, Inc. discovers and develops neuropeptides for the treatment of anxiety and depression based mood disorders. It focuses on the discovery and development of naturally occurring human brain hormones for the treatment of anxiety and depression based mood disorders. The firm products include PT00114 and PT00121, which are peptide-based formulations for the treatment of anxiety and depression disorders. The company is headquartered in New York, NY. | Direttore/Membro del Consiglio | - |
Formazione di Hartoun Hartounian
| University of Delaware | Doctorate Degree |
| University of California, Los Angeles | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| PROTAGENIC THERAPEUTICS, INC. | Health Technology |
| Aziende private | 5 |
|---|---|
Monsanto Co.
 Monsanto Co. Wholesale DistributorsDistribution Services Monsanto Co. engages in the provision of agricultural products to farmers. It provides other seed companies with genetic material and biotechnology traits for their seed brands. The company was founded by John F. Queeny in 1901 and is headquartered in St. Louis, MO. | Distribution Services |
Protagenic Therapeutics, Inc. /Old/
Protagenic Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Protagenic Therapeutics, Inc. discovers and develops neuropeptides for the treatment of anxiety and depression based mood disorders. It focuses on the discovery and development of naturally occurring human brain hormones for the treatment of anxiety and depression based mood disorders. The firm products include PT00114 and PT00121, which are peptide-based formulations for the treatment of anxiety and depression disorders. The company is headquartered in New York, NY. | Health Technology |
MicroIslet, Inc.
MicroIslet, Inc. Miscellaneous Commercial ServicesCommercial Services MicroIslet, Inc. operates as a biotechnology company, which researches, develops, and commercializes patented technologies in the field of transplantation therapy for people with insulin-dependent diabetes. The company was founded on August 21, 1998 and is headquartered in San Diego, CA. | Commercial Services |
| San Diego Tech Coast Angels | |
Vyteris, Inc.
Vyteris, Inc. Pharmaceuticals: MajorHealth Technology Vyteris, Inc. develops, manufactures and commercializes pharmaceutical products. It is engaged in the process of developing first active drug delivery patch to receive marketing clearance from the U.S. Food and Drug Administration. The drug delivery patch technology allows precise dosing, giving physicians and patients control in the rate, dosage and pattern of drug delivery that may result in considerable therapeutic, economical, and lifestyle advantages over existing methods of drug administration. The company was founded on July 19, 2000 and is headquartered in Fair Lawn, NJ. | Health Technology |
- Borsa valori
- Insiders
- Hartoun Hartounian